ProCE Banner Activity

CheckMate 914 (Part A): Adjuvant Nivolumab + Ipilimumab vs Placebo in Localized RCC at High Risk of Relapse Following Nephrectomy

Slideset Download
Conference Coverage
In the phase III CheckMate 914 study, 6 months of adjuvant nivolumab plus ipilimumab following nephrectomy did not improve disease-free survival vs placebo in patients with stage II/III clear-cell RCC at high risk of recurrence.

Released: September 19, 2022

Expiration: September 18, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.